Can genes prevent atherosclerosis?

JAMA

Volumn 276, Issue 12, 1996, Pages 989-992

  Hoeg, Jeffrey M ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CASE REPORT; CHOLESTEROL METABOLISM; CLINICAL FEATURE; DISEASE RESISTANCE; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL;

EID: 0029816288     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.12.989     Document Type: Article

References (48)

1. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte J Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-832.
2. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast CT in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb. 1994;14:1066-1074.
3. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
4. Goldbourt U, Yaari S. Cholesterol and coronary heart disease mortality: a 23-year follow-up study of 9902 men in Israel. Arteriosclerosis. 1990;10:512-519.
5. Rader DJ, Schaefer JR, Lohse P, et al. Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteine, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism. 1993;42:1429-1434.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adulte. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
7. Rifkind BM, Segal P. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. JAMA. 1983;250:1869-1872.
8. Ettinger WH. Lipid levels and risk of atherosclerotic coronary heart disease in the older person. Med Clin North Am. 1989;73:1525-1530.
9. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317:1303-1309.
10. Kannel WB, Neaton JD, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Am Heart J. 1986;112: 825-836.
11. Renaud S, de Lorgeril M. Dietary lipids and their relation to ischaemic heart disease: from epidemiology to prevention. J Intern Med. 1989;225: 39-46.
12. Shekelle RB, Stamler J. Dietary cholesterol and ischaemic heart disease. Lancet. 1989;1:1177-1179.
13. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Book Co; 1995:1981-2030.
14. Hoeg JM. Familial hypercholesterolemia: what the zebra can teach us about the horse. JAMA. 1994;271:543-546.
15. Karathanasis SK, Ferris E, Haddad IA. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A. 1987;84:7198-7202.
16. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989;264:16339-16342.
17. Matsunaga T, Hiasa Y, Yanagi H, et al. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1991;88:2793-2797.
18. Berg K. Twin research in coronary heart disease. Prog Clin Biol Res. 1981;69:117-130.
19. Leaf A. The aging process: lessons from observations in man. Nutr Rev. 1988;46:40-44.
20. Schaefer EJ, Moussa PB, Wilson PW, McGee D, Dallai G, Castelli WP. Plasma lipoproteine in healthy octogenarians: lack of reduced high density lipoprotein cholesterol levels: results from the Framingham Heart Study. Metabolism. 1989;38: 293-296.
21. Lusis AJ. Genetic factors affecting blood lipoproteins: the candidate gene approach 90024. J Lipid Res. 1988;29:397-429.
22. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966;34:679-697.
23. Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1975;1:16-19.
24. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
25. Wilson PW, Abbott RD, Castelli WP. High-density lipoprotein cholesterol and mortality: the Framingham Heart Study. Arteriosclerosis. 1988; 8:737-741.
26. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
27. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res. 1991;32:383-394.
28. Duverger N, Ghalim N, Theret N, et al. Lipoprotein A-I containing particles. Adv Exp Med Biol. 1991;285:93-99.
29. Warden CH, Hedrick CC, Qiao J-H, Castllani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993; 261:469-472.
30. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995;10:1764-1773.
31. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97:1630-1639.
32. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-B1 as a high-density lipoprotein receptor. Science. 1996;271:518-520.
33. Sparks CE, Marsh JB. Metabolic heterogeneity of apolipoprotein B in the rat. J Lipid Res. 1981;22: 519-527.
34. Glueck CJ, Fallat RW, Millett F, Gartside P, Elston RC, Go RCP. Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds. Metabolism. 1975;24:1243-1265.
35. Ikewaki K, Rader DJ, Sakamoto T, et al. Delayed catabolism of high-density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest. 1993;92: 1650-1658.
36. Bruce C, Tall AR. Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol. 1995;6:306-311.
37. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.
38. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postwandial lipemia. Proc Natl Acad Sci U S A. 1983;80:1449-1453.
39. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
40. Hoeg JM, Remaley AT. Reverse cholesterol transport. In: Goldbourt U, de Faire U, Berg K eds. Genetic Factors in Coronary Heart Disease. Norwell. Mass: Kluwer Academic Publishers; 1994;351-369.
41. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
42. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem. 1982;257:6653-6655.
43. 2 synthesis. J Lipid Res. 1985;26:1269-1276.
44. Cheung MC, Wolf AC. In vitro transformation of apoA-1-containing lipoprotein subpopulations: role of lecithin:cholesterol acyltransferase and apoB-containing lipoproteins. J Lipid Res. 1989;30:499-509.
45. Ross JR. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
46. Barbaras R, Puchios P, Fruchart JC, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun. 1987; 142:63-69.
47. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin invest. 1990;85:1234-1241.
48. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.